We get a mention...
" The suppression of CCL5 (RANTES), a chemokine involved in immune cell recruitment, aligns with findings that its receptor, CCR5, plays a role in SARS-CoV-2 pathogenesis. Importantly, blocking CCR5 using leronlimab restored immune homeostasis and reduced IL-6 levels in critically ill COVID-19 patients, suggesting that CCL5 suppression could mitigate prolonged immune activation in long COVID"
https://www.nature.com/articles/s41598-025-23760-y